Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Conditions

• Endometrial Clear Cell Adenocarcinoma
• Endometrial Dedifferentiated Carcinoma
• Endometrial Endometrioid Adenocarcinoma
• Endometrial Mixed Cell Adenocarcinoma
• Endometrial Serous Adenocarcinoma
• Endometrial Undifferentiated Carcinoma
• Recurrent Endometrial Adenocarcinoma
• Recurrent Endometrial Carcinoma
• Recurrent Endometrial Clear Cell Adenocarcinoma
• Recurrent Endometrial Dedifferentiated Carcinoma
• Recurrent Endometrial Endometrioid Adenocarcinoma
• Recurrent Endometrial Mixed Cell Adenocarcinoma
• Recurrent Endometrial Serous Adenocarcinoma
• Recurrent Endometrial Undifferentiated Carcinoma
• Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
• Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

Interventions

• DRUG: Carboplatin
• PROCEDURE: Computed Tomography
• DRUG: Paclitaxel
• BIOLOGICAL: Pembrolizumab
• OTHER: Placebo Administration
• OTHER: Quality-of-Life Assessment
• OTHER: Questionnaire Administration

Sponsor

National Cancer Institute (NCI)

Collaborators

• [object Object]
• [object Object]